News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Minerva Neurosciences, Inc. (NERV) To Ring NASDAQ Stock Market Closing Bell On July 7, 2014


7/7/2014 9:19:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, MD, MBA, Minerva president and CEO, along with additional members of the senior leadership team, will ring the NASDAQ Stock Market Closing Bell this afternoon, July 7, 2014. The ceremony follows the announcement of the pricing of the company's initial public offering on June 30, 2014. Shares began trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014.

"The completion of our IPO was an important milestone in our company history and we are honored to commemorate this event and ring the closing bell at NASDAQ today," said Dr. Vivaldi.

A live webcast of the NASDAQ Closing Bell Ceremony (starting at 3:45 Eastern Time today, July 7) will be available at: https://new.livestream.com/nasdaq/live.

In March of this year, Minerva Neurosciences launched its new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Massachusetts. The establishment of a new corporate headquarters follows the appointment of Rogerio Vivaldi, MD, MBA, as the new president and CEO, and Marc Beer as the chairman of the board of directors of Minerva Neurosciences.

About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc.

Media contact:
Jen Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com

Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com

SOURCE Minerva Neurosciences, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES